- $123.31m
- -$27.94m
- 44
- 39
- 61
- 45
Annual income statement for Sagimet Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 2 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 11.4 | 23.7 | 31.1 | 32.7 | 54.5 |
| Operating Profit | -11.4 | -23.7 | -31.1 | -30.7 | -54.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -11.4 | -24.4 | -30.5 | -27.9 | -45.6 |
| Net Income After Taxes | -11.4 | -24.4 | -30.5 | -27.9 | -45.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -11.4 | -24.4 | -30.5 | -27.9 | -45.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -11.4 | -24.4 | -30.5 | -27.9 | -45.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.528 | -1.13 | -1.42 | -2.66 | -1.45 |
| Dividends per Share |